Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1970 1
1979 1
1981 1
1983 1
1984 2
1985 1
1986 2
1987 1
1989 1
1990 1
1991 1
1993 2
1995 4
1996 2
1997 1
1998 4
1999 6
2000 3
2001 3
2002 3
2003 1
2004 6
2005 4
2006 1
2007 4
2008 4
2009 3
2010 5
2011 5
2012 5
2013 9
2014 6
2015 9
2016 10
2017 9
2018 3
2019 6
2020 17
2021 19
2022 25
2023 24
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Results by year

Filters applied: . Clear all
Page 1
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M; Caravaggio Investigators. Agnelli G, et al. N Engl J Med. 2020 Apr 23;382(17):1599-1607. doi: 10.1056/NEJMoa1915103. Epub 2020 Mar 29. N Engl J Med. 2020. PMID: 32223112 Clinical Trial.
NRF2 and STAT3: friends or foes in carcinogenesis?
Arena A, Romeo MA, Benedetti R, Gilardini Montani MS, Santarelli R, Gonnella R, D'Orazi G, Cirone M. Arena A, et al. Among authors: benedetti r. Discov Oncol. 2023 Mar 31;14(1):37. doi: 10.1007/s12672-023-00644-z. Discov Oncol. 2023. PMID: 37000324 Free PMC article. Review.
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators. Baigent C, et al. Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12. Lancet. 2011. PMID: 21663949 Free PMC article. Clinical Trial.
Epigenetic mechanisms underlying prostate cancer radioresistance.
Macedo-Silva C, Benedetti R, Ciardiello F, Cappabianca S, Jerónimo C, Altucci L. Macedo-Silva C, et al. Among authors: benedetti r. Clin Epigenetics. 2021 Jun 8;13(1):125. doi: 10.1186/s13148-021-01111-8. Clin Epigenetics. 2021. PMID: 34103085 Free PMC article. Review.
Cancer Therapy Resistance: Choosing Kinase Inhibitors.
Dell'Aversana C, Sarno F, Benedetti R, Megchelenbrink WL, Cappetta D. Dell'Aversana C, et al. Among authors: benedetti r. Pharmaceutics. 2024 Mar 7;16(3):373. doi: 10.3390/pharmaceutics16030373. Pharmaceutics. 2024. PMID: 38543267 Free PMC article.
199 results